BS_NH7K4CD9
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- overall_survival_months
- 66.36
- os_event
- false
- age_years
- 1.797
- sex
- M
- e1_e2
- E2
- umap1_2d
- -5.363416491
- umap2_2d
- 0.323559476
- umap1_3d
- 0.418410598
- umap2_3d
- 2.599866658
- umap3_3d
- 0.443479554
- dataset
- EPN-CBTN
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
0 twins match this tumor's tissue · 10 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NH7K4CD9 | Posterior Fossa Ependymoma | — | 0.947 |
| 2 | SRR1475803 | GTEX | — | 0.934 |
| 3 | SRR1334440 | GTEX | — | 0.928 |
| 4 | MDT-AP-1142 | Med | Medulloblastoma | 0.927 |
| 5 | SRR1443979 | GTEX | — | 0.926 |
| 6 | SRR1337431 | GTEX | — | 0.923 |
| 7 | SRR615515 | GTEX | — | 0.922 |
| 8 | SRR658645 | GTEX | — | 0.921 |
| 9 | SRR1390582 | GTEX | — | 0.919 |
| 10 | SRR1416410 | GTEX | — | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.390 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.210 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.180 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |
| COMPLEMENT | 0.020 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.020 | Cobimetinib | — uncovered |